APR 29·Stock TitanLow
[SCHEDULE 13G] Eikon Therapeutics, Inc. Passive Investment Disclosure (>5%)
BlackRock Portfolio Management LLC has disclosed a passive investment in Eikon Therapeutics, Inc. (EIKN), holding 3,002,737 shares, which represents 5.5% of the company's common stock. This Schedule 13G filing indicates a beneficial ownership for passive purposes, with BlackRock exercising sole voting power for 2,939,120 shares and sole dispositive power for all 3,002,737 shares. The disclosure clarifies that these holdings are attributed to specific BlackRock business units and do not signify an intent to influence control over Eikon Therapeutics.